Scholarlink

Background <p>The act of changing an organism’s genetic material to produce mutations, heritable alterations in the nucleotide sequence of DNA or RNA, is known as mutagenesis. Although evolution and natural selection are thought to be primarily driven by mutations, a number of exogenous stimuli, especially some medications, can dramatically speed up the pace of mutation. Because it contributes to the development of resistance to medicinal medicines, the onset and progression of cancer, and congenital defects (teratogenesis), this drug-induced mutagenesis has significant effects on human health.</p> Method of review <p>The purpose of this work is to present a thorough analysis of modern drugs that are known to cause mutagenesis. Based on their main side effects, it classifies these medications as teratogenic, carcinogenic, or directly mutagenic. In order to represent the current state of knowledge in this crucial field of study, the review places special emphasis on discoveries that have been published since 2019.</p> Findings <p>Recent data calls into question the widely held notion that mutations happen unintentionally and gradually. Rather, it implies that stress reactions brought on by medication exposure frequently initiate mutagenesis processes, which are present in all biological systems. This suggests that rather than directly interacting with genetic material, the carcinogenic effects of some medications may occur indirectly as a result of cellular stress. Furthermore, comprehending the intricacies of drug-induced mutagenesis requires an understanding of the interactions among cellular stress, drug exposure, and mutagenic mechanisms.</p> Conclusion <p>The study highlights the need for ongoing research on the mutagenic effects of both new and existing medications. By focusing on studies primarily published since 2019, it aims to provide relevant insights into medication safety protocols and therapeutic approaches to decrease potential patient damage, particularly with relation to teratogenic issues during pregnancy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Molecular mechanisms of drug-induced mutagenesis: a narrative review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月23日

查看全文
  • Tamene Bekele,
  • Abate Wondesen Tsige,
  • Kassahun Dires Ayenew

摘要

Background

The act of changing an organism’s genetic material to produce mutations, heritable alterations in the nucleotide sequence of DNA or RNA, is known as mutagenesis. Although evolution and natural selection are thought to be primarily driven by mutations, a number of exogenous stimuli, especially some medications, can dramatically speed up the pace of mutation. Because it contributes to the development of resistance to medicinal medicines, the onset and progression of cancer, and congenital defects (teratogenesis), this drug-induced mutagenesis has significant effects on human health.

Method of review

The purpose of this work is to present a thorough analysis of modern drugs that are known to cause mutagenesis. Based on their main side effects, it classifies these medications as teratogenic, carcinogenic, or directly mutagenic. In order to represent the current state of knowledge in this crucial field of study, the review places special emphasis on discoveries that have been published since 2019.

Findings

Recent data calls into question the widely held notion that mutations happen unintentionally and gradually. Rather, it implies that stress reactions brought on by medication exposure frequently initiate mutagenesis processes, which are present in all biological systems. This suggests that rather than directly interacting with genetic material, the carcinogenic effects of some medications may occur indirectly as a result of cellular stress. Furthermore, comprehending the intricacies of drug-induced mutagenesis requires an understanding of the interactions among cellular stress, drug exposure, and mutagenic mechanisms.

Conclusion

The study highlights the need for ongoing research on the mutagenic effects of both new and existing medications. By focusing on studies primarily published since 2019, it aims to provide relevant insights into medication safety protocols and therapeutic approaches to decrease potential patient damage, particularly with relation to teratogenic issues during pregnancy.